Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Juan Manuel Alonso-Dominguez, MD, Felipe Casado, MariaTeresa Gómez Casares, MDPhD, Ismael Buno, Francisca Ferrer-Marin, Eduardo Anguita, MD PhD, Alicia Arenas, Rafael Del Orbe, MD, Rosa M. Ayala, MD PhD, Pilar Llamas, MD, Pedro Sanchez-Godoy, MD, Carmen Burgaleta, MD, Valentín García-Gutierrez, Juan Luis Steegmann, MD PhD, Joaquin Martinez-Lopez

Blood (2015) 126 (23): 2791.

https://doi.org/10.1182/blood.V126.23.2791.2791

Published: 2015

Journal Articles

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Blood (2015) 126 (23): 1602.

https://doi.org/10.1182/blood.V126.23.1602.1602

Published: 2015

Journal Articles

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Esther Onecha, Joan Ballesteros, Jose L Rojas, Jose M Sanchez, Eva Barragan, PhD, Inmaculada Rapado, PhD, Santiago Barrio, David Martinez, MD PhD, Pau Montesinos, MD, Pilar Herrera, MD PhD, Carmen Burgaleta, MD, Joaquin Martinez-López, MDPhD, Rosa M. Ayala, MD PhD

Blood (2015) 126 (23): 1376.

https://doi.org/10.1182/blood.V126.23.1376.1376

Published: 2015

Journal Articles

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pau Montesinos, MD, Joan Ballesteros, David Martínez-Cuadrón, Joaquín Martínez-López, Josefina Serrano, Jaime Perez de Oteyza, Pascual Fernández, Gabriela Rodriguez-Macías, Mª Belén Vidriales, Pilar Herrera, MD PhD, Mar Tormo, MD PhD, Juan Bergua, Raimundo García, MD, Susana Vives, Mª Ángeles Fernández, Esperanza Lavilla, MD, Santiago Jimenez, Jose Antonio Pérez-Simón, Adriana Simiele, Ataulfo González, Bernardo J. González, Carmen Burgaleta, Juan Antonio López, Concepción Bethancourt, Guiomar Bautista, Arancha Alonso, Mercedes Colorado, Jordi Sierra, Begoña Navas, José Angel Hernández-Rivas, Juan Antonio Vera, Mª Lourdes Amador, Raúl Cordoba, MD, Adolfo de la Fuente, Fernando Ramos, MD PhD MPH, Carlos Javier Cerveró, Consolación Rayón, Olga Salamero, Edelmira Martí, Aurelio López, Teresa Olavé, Marta Gaspar, Julian Gorrochategui, José Luis Rojas, Cristina Gomez, Pilar Hernández, Alicia Robles, Ignacio Ortega, Jesús Villoria, Federico Moscardó, Iñaki Troconiz, Miguel A. Sanz, MD PhD

Blood (2015) 126 (23): 4837.

https://doi.org/10.1182/blood.V126.23.4837.4837

Published: 2015

Journal Articles

Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders

Blood (2013) 122 (21): 3923.

https://doi.org/10.1182/blood.V122.21.3923.3923

Published: 2013

Journal Articles

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Blood (2013) 122 (21): 1294.

https://doi.org/10.1182/blood.V122.21.1294.1294

Published: 2013

Journal Articles

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Blood (2013) 122 (21): 1347.

https://doi.org/10.1182/blood.V122.21.1347.1347

Published: 2013

Journal Articles

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Blood (2012) 120 (21): 4599.

https://doi.org/10.1182/blood.V120.21.4599.4599

Published: 2012

Journal Articles

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel de Paz, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Ángel Hernández-Rivas, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3764.

https://doi.org/10.1182/blood.V120.21.3764.3764

Published: 2012

Journal Articles

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel De Paz, MD, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Angel Hernandez-rivas, MD, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3768.

https://doi.org/10.1182/blood.V120.21.3768.3768

Published: 2012

Journal Articles

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Blood (2012) 120 (21): 3762.

https://doi.org/10.1182/blood.V120.21.3762.3762

Published: 2012

Journal Articles

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms

Santiago Barrio, Miguel Gallardo, Alicia Arenas, Rosa M. Ayala, MD, PhD, Inmaculada Rapado, Daniel Rueda, PhD, Ana Jimenez, Enriqueta Albizua, Carmen Burgaleta, Florinda Gilsanz, MD, PhD, Joaquin Martinez, MD

Blood (2012) 120 (21): 5054.

https://doi.org/10.1182/blood.V120.21.5054.5054

Published: 2012

Journal Articles

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Alberto Alvarez-Larrán, Arturo Pereira, Francisco Cervantes, Eduardo Arellano-Rodrigo, Juan-Carlos Hernández-Boluda, Francisca Ferrer-Marín, Anna Angona, Montse Gómez, Begoña Muiña, Helga Guillén, Anabel Teruel, Beatriz Bellosillo, Carmen Burgaleta, Vicente Vicente, Carles Besses

Blood (2012) 119 (6): 1363–1369.

https://doi.org/10.1182/blood-2011-10-387787

Published: 2012

Journal Articles

Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)

Patricia Font, PhD, Valle Gomez Garcia De Soria, PhD, Javier Loscertales, PhD, Julio Garcia Suarez, PhD, Marta Callejas, PhD, Carmen Burgaleta, PhD, Santiago Osorio, PhD, Carlos Soto, PhD, Lucia Villalon, PhD, Jose Diez-Martin, Ana Villegas, PhD

Blood (2010) 116 (21): 4973.

https://doi.org/10.1182/blood.V116.21.4973.4973

Published: 2010

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

Alberto Alvarez-Larrán, Francisco Cervantes, Arturo Pereira, Eduardo Arellano-Rodrigo, Virginia Pérez-Andreu, Juan-Carlos Hernández-Boluda, Ramón Ayats, Carlos Salvador, Ana Muntañola, Beatriz Bellosillo, Vicente Vicente, Luis Hernández-Nieto, Carmen Burgaleta, Blanca Xicoy, Carlos Besses

Blood (2010) 116 (8): 1205–1210.

https://doi.org/10.1182/blood-2010-01-263319

Published: 2010

Journal Articles

Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment.

Alberto Alvarez-Larrán, Francisco Cervantes, Eduardo Arellano-Rodrigo, Virginia Pérez-Andreu, Juan-Carlos Hernández-Boluda, Carlos Salvador, Ramón Ayats, Anna Muntañola, Beatriz Bellosillo, Vicente Vicente, Carmen Burgaleta, Anna Gaya, Luis Hernández-Nieto, Blanca Xicoy, Carlos Besses

Blood (2009) 114 (22): 3906.

https://doi.org/10.1182/blood.V114.22.3906.3906

Published: 2009

Journal Articles

Newly acquired chromosome Abnormalities During Course of CLL: a Retrospective Collection Data From 2 Spanish Centers.

Javier Loscertales, MD, Eva Arranz, PhD, Maria-Angeles Sanz, PhD, Carmen Burgaleta, MD, PhD, Juan-José Gil-Fernández, MD, PhD, Juan Luis Steegmann, MD, PhD, Adrian Alegre, MD

Blood (2009) 114 (22): 4384.

https://doi.org/10.1182/blood.V114.22.4384.4384

Published: 2009

Journal Articles

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Luis Felipe Casado, MD, PhD, Isabel Massague, MD, Pilar Giraldo, MD, Manuel Pérez-Encinas, MD, Raquel de Paz, MD, PhD, Joaquin Martínez-López, MD, PhD, Rafael Fores, MD, Santiago Osorio, MD, Maria José Requena, MD, Luis Palomera, MD, María Jesus Peñarrubia, MD, Carmen Burgaleta, MD, PhD, Begoña Maestro, PhD, Juan Luis Steegmann, MD, PhD

Blood (2009) 114 (22): 1121.

https://doi.org/10.1182/blood.V114.22.1121.1121

Published: 2009

Journal Articles

Induction with Fludarabine, Cyclophosphamide and Rituximab as Front-Line Therapy Against Follicular Lymphoma: Results from a Cooperative Spanish Trial

Blood (2007) 110 (11): 1286.

https://doi.org/10.1182/blood.V110.11.1286.1286

Published: 2007

NARROW

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment.

Newly acquired chromosome Abnormalities During Course of CLL: a Retrospective Collection Data From 2 Spanish Centers.

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Induction with Fludarabine, Cyclophosphamide and Rituximab as Front-Line Therapy Against Follicular Lymphoma: Results from a Cooperative Spanish Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only